Diagnostic Imaging Partnering Terms and Agreements
Published: Aug 2014 | Publisher: Current Partnering | Pages: 834SUMMARY
The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering deals and agreements entered into by the worlds leading healthcare companies.
TABLE OF CONTENTS
Executive Summary
Chapter 1 Introduction
Chapter 2 Trends in diagnostic imaging dealmaking
2.1. Introduction
2.2. Diagnostic imaging partnering over the years
2.3. Big pharma diagnostic imaging dealmaking activity
2.4. Most active in diagnostic imaging partnering
2.5. Diagnostic imaging partnering by industry sector
2.6. Diagnostic imaging partnering by deal type
2.7. Diagnostic imaging partnering by disease type
2.8. Diagnostic imaging partnering by specific technology type
2.9. Average deal terms for diagnostic imaging partnering
2.9.1 Diagnostic imaging headline values
2.9.2 Diagnostic imaging upfront payments
2.9.3 Diagnostic imaging milestone payments
2.9.4 Diagnostic imaging royalty rates
2.10. The anatomy of diagnostic imaging partnering
2.10. The anatomy of a diagnostic imaging deal
2.10.a. Case study : Vaso Diagnostics- GE Healthcare: July 2010
Chapter 3 Leading diagnostic imaging deals
3.1. Introduction
3.2. Top diagnostic imaging deals by value
Chapter 4 Big pharma diagnostic imaging deals
4.1. Introduction
4.2. How to use big pharma diagnostic imaging partnering deals
4.3. Big pharma diagnostic imaging partnering company profiles
Abbott
Actavis (acquired by Watson)
AstraZeneca
Bayer
Eisai
Eli Lilly
GlaxoSmithKline
Lundbeck
Merck & Co
Merck KGaA
Novartis
Roche
Sanofi
Servier
Chapter 5 Diagnostic imaging partnering contracts directory
5.1. Introduction
5.2. Company A-Z
Actavis (acquired by Watson)
Acusphere
Audeo Oncology
Beijing Double-Crane Pharmaceutical
Bio-Imaging Technologies
BioClinica
Biofield
Biotage
Caliper Life Sciences
Cantel Medical (UK)
Cryolife
Dr Faupel
Esaote
GE Healthcare
General Electric (GE)
Guided Therapeutics
IsoRay
Konica Minolta
Lantheus Medical Imaging
MDS Nordion
Misonix
Norgine
Novel Laboratories
Pharmalucence
Salix Pharmaceuticals
Siemens
SonoSite
Starch Medical
SurgiVision
Techniscan
USHIFU
Vaso Diagnostics
Vasomedical
5.3. By deal type
Asset purchase
Co-development
Contract service
Development
Distribution
Licensing
Manufacturing
Marketing
Option
Promotion
Settlement
Sub-license
Supply
Technology transfer
Termination
5.4. By stage of development
Preclinical
Phase III
Regulatory
Marketed
5.5. By therapy area
Cardiovascular
Dermatology
Gastrointestinal
Hematology
Hospital care
Oncology
Chapter 6 Diagnostic imaging dealmaking by specific imaging type
6.1. Introduction
6.2. Deals by diagnostic imaging type
Appendices
Introduction
Appendix 1 Directory of diagnostic imaging deals by company A-Z 2009 to 2014
Appendix 2 Directory of diagnostic imaging deals by stage of development 2009 to 2014
Appendix 3 Directory of diagnostic imaging deals by deal type 2009 to 2014
Appendix 4 Directory of diagnostic imaging deals by therapy area 2009 to 2014
Appendix 5 Diagnostic Imaging partnering resource center
Online diagnostic imaging partnering
Diagnostic Imaging partnering events
Further reading on diagnostic imaging dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form Technology Reports
Order Form Upgrades to subscription access products
Table of figures
Figure 1: Diagnostic imaging partnering since 2009
Figure 2: Big pharma top 50 Diagnostic imaging deals 2009 to 2014
Figure 3: Big pharma diagnostic imaging deal frequency 2009 to 2014
Figure 4: Active diagnostic imaging dealmaking activity 2009 to 2014
Figure 5: Diagnostic imaging partnering by industry sector since 2009
Figure 6: Diagnostic imaging partnering by deal type since 2009
Figure 7: Diagnostic imaging partnering by disease type since 2009
Figure 8: Diagnostic imaging partnering by disease type since 2009
Figure 9: Diagnostic imaging deals with a headline value
Figure 10: Diagnostic imaging deal headline value distribution, US$million discovery stage
Figure 11: Diagnostic imaging deal headline value distribution, US$million preclinical stage
Figure 12: Diagnostic imaging deal headline value distribution, US$million phase I stage
Figure 13: Diagnostic imaging deal headline value distribution, US$million phase II stage
Figure 14: Diagnostic imaging deal headline value distribution, US$million phase III stage
Figure 15: Diagnostic imaging deal headline value distribution, US$million regulatory stage
Figure 16: Diagnostic imaging deal headline value distribution, US$million marketed stage
Figure 17: Summary median headline value by stage of development, 2009-2014
Figure 18: Diagnostic imaging deals with upfront payment values
Figure 19: Diagnostic imaging deal upfront payment distribution, US$million discovery stage
Figure 20: Diagnostic imaging deal upfront payment distribution, US$million preclinical stage
Figure 21: Diagnostic imaging deal upfront payment distribution, US$million phase I stage
Figure 22: Diagnostic imaging deal upfront payment distribution, US$million phase II stage
Figure 23: Diagnostic imaging deal upfront payment distribution, US$million phase III stage
Figure 24: Diagnostic imaging deal upfront payment distribution, US$million regulatory stage
Figure 25: Diagnostic imaging deal upfront payment distribution, US$million marketed stage
Figure 26: Summary median upfront payments by stage of development, 2009-2014
Figure 27: Diagnostic imaging deals with milestone payments
Figure 28: Diagnostic imaging deal milestone distribution, US$million discovery stage
Figure 29: Diagnostic imaging deal milestone distribution, US$million preclinical stage
Figure 30: Diagnostic imaging deal milestone distribution, US$million phase I stage
Figure 31: Diagnostic imaging deal milestone distribution, US$million phase II stage
Figure 32: Diagnostic imaging deal milestone distribution, US$million phase III stage
Figure 33: Diagnostic imaging deal milestone distribution, US$million regulatory stage
Figure 34: Diagnostic imaging deal milestone distribution, US$million marketed stage
Figure 35: Diagnostic imaging deals with royalty rates, %
Figure 36: Diagnostic imaging deal royalty rate distribution, US$million discovery stage
Figure 37: Diagnostic imaging deal royalty rate distribution, US$million preclinical stage
Figure 38: Diagnostic imaging deal royalty rate distribution, US$million phase I stage
Figure 39: Diagnostic imaging deal royalty rate distribution, US$million phase II stage
Figure 40: Diagnostic imaging deal royalty rate distribution, US$million phase III stage
Figure 41: Diagnostic imaging deal royalty rate distribution, US$million regulatory stage
Figure 42: Diagnostic imaging deal royalty rate distribution, US$million marketed stage
Figure 43: Summary median royalty rate by stage of development, 2009-2014
Figure 44: Components of the typical diagnostic imaging deal structure
Figure 45: Top diagnostic imaging deals by value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events
Chapter 1 Introduction
Chapter 2 Trends in diagnostic imaging dealmaking
2.1. Introduction
2.2. Diagnostic imaging partnering over the years
2.3. Big pharma diagnostic imaging dealmaking activity
2.4. Most active in diagnostic imaging partnering
2.5. Diagnostic imaging partnering by industry sector
2.6. Diagnostic imaging partnering by deal type
2.7. Diagnostic imaging partnering by disease type
2.8. Diagnostic imaging partnering by specific technology type
2.9. Average deal terms for diagnostic imaging partnering
2.9.1 Diagnostic imaging headline values
2.9.2 Diagnostic imaging upfront payments
2.9.3 Diagnostic imaging milestone payments
2.9.4 Diagnostic imaging royalty rates
2.10. The anatomy of diagnostic imaging partnering
2.10. The anatomy of a diagnostic imaging deal
2.10.a. Case study : Vaso Diagnostics- GE Healthcare: July 2010
Chapter 3 Leading diagnostic imaging deals
3.1. Introduction
3.2. Top diagnostic imaging deals by value
Chapter 4 Big pharma diagnostic imaging deals
4.1. Introduction
4.2. How to use big pharma diagnostic imaging partnering deals
4.3. Big pharma diagnostic imaging partnering company profiles
Abbott
Actavis (acquired by Watson)
AstraZeneca
Bayer
Eisai
Eli Lilly
GlaxoSmithKline
Lundbeck
Merck & Co
Merck KGaA
Novartis
Roche
Sanofi
Servier
Chapter 5 Diagnostic imaging partnering contracts directory
5.1. Introduction
5.2. Company A-Z
Actavis (acquired by Watson)
Acusphere
Audeo Oncology
Beijing Double-Crane Pharmaceutical
Bio-Imaging Technologies
BioClinica
Biofield
Biotage
Caliper Life Sciences
Cantel Medical (UK)
Cryolife
Dr Faupel
Esaote
GE Healthcare
General Electric (GE)
Guided Therapeutics
IsoRay
Konica Minolta
Lantheus Medical Imaging
MDS Nordion
Misonix
Norgine
Novel Laboratories
Pharmalucence
Salix Pharmaceuticals
Siemens
SonoSite
Starch Medical
SurgiVision
Techniscan
USHIFU
Vaso Diagnostics
Vasomedical
5.3. By deal type
Asset purchase
Co-development
Contract service
Development
Distribution
Licensing
Manufacturing
Marketing
Option
Promotion
Settlement
Sub-license
Supply
Technology transfer
Termination
5.4. By stage of development
Preclinical
Phase III
Regulatory
Marketed
5.5. By therapy area
Cardiovascular
Dermatology
Gastrointestinal
Hematology
Hospital care
Oncology
Chapter 6 Diagnostic imaging dealmaking by specific imaging type
6.1. Introduction
6.2. Deals by diagnostic imaging type
Appendices
Introduction
Appendix 1 Directory of diagnostic imaging deals by company A-Z 2009 to 2014
Appendix 2 Directory of diagnostic imaging deals by stage of development 2009 to 2014
Appendix 3 Directory of diagnostic imaging deals by deal type 2009 to 2014
Appendix 4 Directory of diagnostic imaging deals by therapy area 2009 to 2014
Appendix 5 Diagnostic Imaging partnering resource center
Online diagnostic imaging partnering
Diagnostic Imaging partnering events
Further reading on diagnostic imaging dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form Technology Reports
Order Form Upgrades to subscription access products
Table of figures
Figure 1: Diagnostic imaging partnering since 2009
Figure 2: Big pharma top 50 Diagnostic imaging deals 2009 to 2014
Figure 3: Big pharma diagnostic imaging deal frequency 2009 to 2014
Figure 4: Active diagnostic imaging dealmaking activity 2009 to 2014
Figure 5: Diagnostic imaging partnering by industry sector since 2009
Figure 6: Diagnostic imaging partnering by deal type since 2009
Figure 7: Diagnostic imaging partnering by disease type since 2009
Figure 8: Diagnostic imaging partnering by disease type since 2009
Figure 9: Diagnostic imaging deals with a headline value
Figure 10: Diagnostic imaging deal headline value distribution, US$million discovery stage
Figure 11: Diagnostic imaging deal headline value distribution, US$million preclinical stage
Figure 12: Diagnostic imaging deal headline value distribution, US$million phase I stage
Figure 13: Diagnostic imaging deal headline value distribution, US$million phase II stage
Figure 14: Diagnostic imaging deal headline value distribution, US$million phase III stage
Figure 15: Diagnostic imaging deal headline value distribution, US$million regulatory stage
Figure 16: Diagnostic imaging deal headline value distribution, US$million marketed stage
Figure 17: Summary median headline value by stage of development, 2009-2014
Figure 18: Diagnostic imaging deals with upfront payment values
Figure 19: Diagnostic imaging deal upfront payment distribution, US$million discovery stage
Figure 20: Diagnostic imaging deal upfront payment distribution, US$million preclinical stage
Figure 21: Diagnostic imaging deal upfront payment distribution, US$million phase I stage
Figure 22: Diagnostic imaging deal upfront payment distribution, US$million phase II stage
Figure 23: Diagnostic imaging deal upfront payment distribution, US$million phase III stage
Figure 24: Diagnostic imaging deal upfront payment distribution, US$million regulatory stage
Figure 25: Diagnostic imaging deal upfront payment distribution, US$million marketed stage
Figure 26: Summary median upfront payments by stage of development, 2009-2014
Figure 27: Diagnostic imaging deals with milestone payments
Figure 28: Diagnostic imaging deal milestone distribution, US$million discovery stage
Figure 29: Diagnostic imaging deal milestone distribution, US$million preclinical stage
Figure 30: Diagnostic imaging deal milestone distribution, US$million phase I stage
Figure 31: Diagnostic imaging deal milestone distribution, US$million phase II stage
Figure 32: Diagnostic imaging deal milestone distribution, US$million phase III stage
Figure 33: Diagnostic imaging deal milestone distribution, US$million regulatory stage
Figure 34: Diagnostic imaging deal milestone distribution, US$million marketed stage
Figure 35: Diagnostic imaging deals with royalty rates, %
Figure 36: Diagnostic imaging deal royalty rate distribution, US$million discovery stage
Figure 37: Diagnostic imaging deal royalty rate distribution, US$million preclinical stage
Figure 38: Diagnostic imaging deal royalty rate distribution, US$million phase I stage
Figure 39: Diagnostic imaging deal royalty rate distribution, US$million phase II stage
Figure 40: Diagnostic imaging deal royalty rate distribution, US$million phase III stage
Figure 41: Diagnostic imaging deal royalty rate distribution, US$million regulatory stage
Figure 42: Diagnostic imaging deal royalty rate distribution, US$million marketed stage
Figure 43: Summary median royalty rate by stage of development, 2009-2014
Figure 44: Components of the typical diagnostic imaging deal structure
Figure 45: Top diagnostic imaging deals by value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events
$2,995
My Basket
 | Diagnostic Imaging Partnering Terms and Agreements | $2,995 |
| TOTAL | $2,995 | |
| Empty Cart | ||
| ||
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed